BioCentury
ARTICLE | Clinical News

SPD 502 (NS1209): Began Phase I trial

November 1, 1999 8:00 AM UTC

Shire Pharmaceuticals Group plc (LSE:SHP; SHPGY), Andover, U.K. Product: SPD 502 ( NS1209) Business: Neurological Therapeutic category: Receptor antagonist Target: AMPA receptor Description: Water-s...